Stryker (NYSE:SYK) has received mixed analyst ratings over the past three months, with 7 analysts offering views ranging from bullish to indifferent. The average 12-month price target for SYK has increased by 10.1% to $324.57, with a high estimate of $345.00 and a low of $297.00. Analysts from RBC Capital, Truist Securities, Morgan Stanley, Roth MKM, and UBS have adjusted their ratings and price targets, reflecting a positive outlook on the company's performance. Stryker is a major player in medical equipment and has shown strong financial indicators such as a 9.6% revenue growth rate, a net margin of 14.1%, and an ROA of 1.83%, but a lower-than-average ROE of 3.92% and a conservative debt-to-equity ratio of 0.71.